Digestive Diseases and Sciences

, Volume 58, Issue 10, pp 2933–2939 | Cite as

The Value of Early Wireless Esophageal pH Monitoring in Diagnosing Functional Heartburn in Refractory Gastroesophageal Reflux Disease

  • Eun-Young Park
  • Myung-Gyu ChoiEmail author
  • Meonggi Baeg
  • Chul-Hyun Lim
  • Jinsu Kim
  • Yukyung Cho
  • Jaemyung Park
  • Inseok Lee
  • Sangwoo Kim
  • Kyuyong Choi
Original Article


Background and Aims

It is difficult to differentiate functional heartburn from proton pump inhibitor (PPI) failure. The aims of this study were to assess the role of early wireless esophageal pH monitoring in patients referred with gastroesophageal reflux disease (GERD) and to identify differences in the clinical spectrum among GERD subtypes.


We enrolled consecutive referred patients with suspected GERD. After endoscopy on the first visit, all underwent wireless esophageal pH monitoring when off the PPI.


Two hundred thirty patients were enrolled. These patients were classified into a reflux esophagitis group (20, 8.7 %) and a normal endoscopic findings group (210, 91.3 %). Among the 210 patients in the normal endoscopic findings group, 63 (27.4 %) were diagnosed with pathological reflux, 35 (15.2 %) with hypersensitive esophagus, 87 (37.8 %) with normal acid exposure with negative symptom association, and 25 (10.9 %) with test failure. These groups did not differ in age, body mass index, smoking habit, alcohol consumption, symptom severity, quality of life, presence of atypical symptoms, overlap with irritable bowel syndrome, and the frequency of somatization, depression, and anxiety. PPI responses were evaluated in 135 patients. Fifty patients (37.0 %) were not responsive to the 4-week treatment; 26 (19.3 %) were diagnosed with refractory non-erosive gastroesophageal disease, and 24 (17.8 %) with functional heartburn. The demographics and clinical and psychological characteristics did not differ between the two groups.


Demographic characteristics and symptom patterns alone cannot differentiate functional heartburn from various subtypes of GERD. Wireless esophageal pH monitoring should be considered for the initial evaluation of GERD in the tertiary referral setting.


Esophageal pH monitoring Gastroesophageal reflux Heartburn Proton pump inhibitors 



This work was supported by research grant from Jeil Pharmaceuticals Co, Ltd.

Conflict of interest



  1. 1.
    Sifrim D, Zerbib F. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors. Gut. 2012;61:1340–1354.PubMedCrossRefGoogle Scholar
  2. 2.
    Hershcovici T, Fass R. An algorithm for diagnosis and treatment of refractory GERD. Best Pract Res Clin Gastroenterol. 2010;24:923–936.PubMedCrossRefGoogle Scholar
  3. 3.
    Dickman R, Boaz M, Aizic S, et al. Comparison of clinical characteristics of patients with gastroesophageal reflux disease who failed proton pump inhibitor therapy versus those who fully responded. J Neurogastroenterol Motil. 2011;17:387–394.PubMedCrossRefGoogle Scholar
  4. 4.
    Hershcovici T, Fass R. Step-by-step management of refractory gastroesophageal reflux disease. Dis Esophagus. 2013;26:27–36.PubMedCrossRefGoogle Scholar
  5. 5.
    Cho YK, Choi MG, Lim CH, et al. Diagnostic value of the PPI test for detection of GERD in Korean patients and factors associated with PPI responsiveness. Scand J Gastroenterol. 2010;45:533–539.PubMedCrossRefGoogle Scholar
  6. 6.
    Hershcovici T, Fass R. Nonerosive reflux disease (NERD)—an update. J Neurogastroenterol Motil. 2010;16:8–21.PubMedCrossRefGoogle Scholar
  7. 7.
    Lee WC, Yeh YC, Lacy BE, et al. Timely confirmation of gastro-esophageal reflux disease via pH monitoring: estimating budget impact on managed care organizations. Curr Med Res Opin. 2008;24:1317–1327.PubMedCrossRefGoogle Scholar
  8. 8.
    Fass R. Therapeutic options for refractory gastroesophageal reflux disease. J Gastroenterol Hepatol. 2012;27:3–7.PubMedCrossRefGoogle Scholar
  9. 9.
    van der Velden AW, de Wit NJ, Quartero AO, et al. Pharmacological dependency in chronic treatment of gastroesophageal reflux disease: a randomized controlled clinical trial. Digestion. 2010;81:43–52.PubMedCrossRefGoogle Scholar
  10. 10.
    Frazzoni M, De Micheli E, Zentilin P, et al. Pathophysiological characteristics of patients with non-erosive reflux disease differ from those of patients with functional heartburn. Aliment Pharmacol Ther. 2004;20:81–88.PubMedCrossRefGoogle Scholar
  11. 11.
    Richter JE. How to manage refractory GERD. Nat Clin Pract Gastroenterol Hepatol. 2007;4:658–664.PubMedCrossRefGoogle Scholar
  12. 12.
    Ke MY. How to differentiate non-erosive reflux disease from functional heartburn. J Dig Dis. 2012;13:605–608.PubMedCrossRefGoogle Scholar
  13. 13.
    Azzam R, Sallum R, Brandao J, et al. Comparative study of two modes of gastroesophageal reflux measuring: conventional esophageal pH monitoring and wireless pH monitoring. Arq Gastroenterol. 2012;49:107–112.PubMedCrossRefGoogle Scholar
  14. 14.
    Ang D, Teo EK, Ang TL, et al. To Bravo or not? A comparison of wireless esophageal pH monitoring and conventional pH catheter to evaluate non-erosive gastroesophageal reflux disease in a multiracial Asian cohort. J Dig Dis. 2010;11:19–27.PubMedCrossRefGoogle Scholar
  15. 15.
    Roman S, Mion F, Zerbib F, et al. Wireless pH capsule–yield in clinical practice. Endoscopy. 2012;44:270–276.PubMedCrossRefGoogle Scholar
  16. 16.
    Wenner J, Johnsson F, Johansson J, et al. Wireless esophageal pH monitoring is better tolerated than the catheter-based technique: results from a randomized cross-over trial. Am J Gastroenterol. 2007;102:239–245.PubMedCrossRefGoogle Scholar
  17. 17.
    Ang D, Teo EK, Ang TL, et al. To Bravo or not? A comparison of wireless esophageal pH monitoring and conventional pH catheter to evaluate non-erosive gastroesophageal reflux disease in a multiracial Asian cohort. J Dig Dis. 2010;11:19–27.PubMedCrossRefGoogle Scholar
  18. 18.
    de Hoyos A, Esparza EA. Technical problems produced by the Bravo pH test in nonerosive reflux disease patients. World J Gastroenterol. 2010;16:3183–3186.PubMedCrossRefGoogle Scholar
  19. 19.
    Sweis R, Fox M, Anggiansah A, et al. Prolonged, wireless pH-studies have a high diagnostic yield in patients with reflux symptoms and negative 24-h catheter-based pH-studies. Neurogastroenterol Motil. 2011;23:419–426.PubMedCrossRefGoogle Scholar
  20. 20.
    Sweis R, Fox M, Anggiansah R, et al. Patient acceptance and clinical impact of Bravo monitoring in patients with previous failed catheter-based studies. Aliment Pharmacol Ther. 2009;29:669–676.PubMedCrossRefGoogle Scholar
  21. 21.
    Martinez S, Malagon I, Garewal H, et al. Non-erosive reflux disease (NERD)-acid reflux and symptom patterns. Aliment Pharmacol Ther. 2003;17:537–545.PubMedCrossRefGoogle Scholar
  22. 22.
    Bytzer P, Jones R, Vakil N, et al. Limited ability of the proton-pump inhibitor test to identify patients with gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2012;10:1360–1366.PubMedCrossRefGoogle Scholar
  23. 23.
    de Leone A, Tonini M, Dominici P, et al. The proton pump inhibitor test for gastroesophageal reflux disease: optimal cut-off value and duration. Dig Liver Dis. 2010;42:785–790.PubMedCrossRefGoogle Scholar
  24. 24.
    Lee JS. Is wireless capsule pH monitoring better than catheter systems? J Neurogastroenterol Motil. 2012;18:117–119.PubMedCrossRefGoogle Scholar
  25. 25.
    Cabrera J, Davis M, Horn D, et al. Esophageal pH monitoring with the BRAVO capsule: experience in a single tertiary medical center. J Pediatr Gastroenterol Nutr. 2011;53:404–408.PubMedGoogle Scholar
  26. 26.
    Lacy BE, Weiser K, Chertoff J, et al. The diagnosis of gastroesophageal reflux disease. Am J Med. 2010;123:583–592.PubMedCrossRefGoogle Scholar
  27. 27.
    Karamanolis G, Kotsalidis G, Triantafyllou K, et al. Yield of combined impedance-pH monitoring for refractory reflux symptoms in clinical practice. J Neurogastroenterol Motil. 2011;17:158–163.PubMedCrossRefGoogle Scholar
  28. 28.
    Hirano I, Richter JE. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol. 2007;102:668–685.PubMedCrossRefGoogle Scholar
  29. 29.
    Furuta T, Shimatani T, Sugimoto M, et al. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan. J Gastroenterol. 2011;46:1273–1283.PubMedCrossRefGoogle Scholar
  30. 30.
    Kusano M, Hongo M, Miwa H. Response to gastroesophageal reflux disease therapy: assessment at 4 weeks predicts response/non-response at 8 weeks. Digestion. 2012;85:282–287.PubMedCrossRefGoogle Scholar
  31. 31.
    Hemmink GJ, Bredenoord AJ, Weusten BL, et al. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: “on” or “off” proton pump inhibitor? Am J Gastroenterol. 2008;103:2446–2453.PubMedCrossRefGoogle Scholar
  32. 32.
    Zerbib F, Belhocine K, Simon M, et al. Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease. Gut. 2012;61:501–506.PubMedCrossRefGoogle Scholar
  33. 33.
    Savarino E, Marabotto E, Zentilin P, et al. The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease. Dig Liver Dis. 2011;43:542–547.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Eun-Young Park
    • 1
  • Myung-Gyu Choi
    • 1
    Email author
  • Meonggi Baeg
    • 1
  • Chul-Hyun Lim
    • 1
  • Jinsu Kim
    • 1
  • Yukyung Cho
    • 1
  • Jaemyung Park
    • 1
  • Inseok Lee
    • 1
  • Sangwoo Kim
    • 1
  • Kyuyong Choi
    • 1
  1. 1.Division of Gastroenterology, Department of Internal Medicine, Seoul St. Mary’s HospitalThe Catholic University of KoreaSeoulKorea

Personalised recommendations